NeoGenomics (NASDAQ: NEO) reported Q3 EPS of $0.01, $0.01 worse than the analyst estimate of $0.02. Revenue for the quarter came in at $63.1 million versus the consensus estimate of $63.88 million.

(2) to be $9 - $10 million, Adjusted Net Income(2) to be $0.04 - $0.05 per share.

GUIDANCE:

NeoGenomics sees Q4 2017 EPS of $0.04-$0.05, versus the consensus of $0.04. NeoGenomics sees Q4 2017 revenue of $65-67 million, versus the consensus of $67.1 million.

11% reduction in average cost per clinical genetic test

• GAAP EPS of ($0.10) per share and non-GAAP Adj. Diluted EPS

  For earnings history and earnings-related data on NeoGenomics (NEO) click here.